title: Long-term efficacy of adalimumab in hyperimmunoglobulin D and periodic fever syndrome.
authors.forename: Marcella
authors.initials: M
authors.lastname: Di Gangi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Amato
authors.forename: Giovanni
authors.initials: G
authors.lastname: Converso
authors.forename: Alessia
authors.initials: A
authors.lastname: Benenati
authors.forename: Concetta
authors.initials: C
authors.lastname: Leonetti
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Borella
authors.forename: Andrea
authors.initials: A
authors.lastname: Doria
authors.forename: Rosario
authors.initials: R
authors.lastname: Foti
mesh_terms: D000210:Acute-Phase Reaction / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D003598:Cytoskeletal Proteins / Q000235:genetics; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D054078:Mevalonate Kinase Deficiency / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D009154:Mutation; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics*; D000071198:Pyrin; D012074:Remission Induction; D058566:Sacroiliitis / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D013995:Time; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D003598:Cytoskeletal Proteins; D005819:Genetic Markers; D000071198:Pyrin; D014409:Tumor Necrosis Factor-alpha; D017853:Phosphotransferases (Alcohol Group Acceptor); C021796:mevalonate kinase; D000068879:Adalimumab